Alemtuzumab as compared to alternative contemporary induction regimens

Summary Between 1 January 2002 and 31 December 2007, our center performed 1687 adult renal transplants. A retrospective analysis was performed to compare outcomes between patients receiving alemtuzumab (n = 632) and those receiving either basiliximab (n = 690) or thymoglobulin (n = 125). Patients re...

Full description

Saved in:
Bibliographic Details
Published in:Transplant international 2012-05, Vol.25 (5), p.518-526
Main Authors: LaMattina, John C., Mezrich, Joshua D., Michael Hofmann, R., Foley, David P., D'Alessandro, Anthony M., Sollinger, Hans W., Pirsch, John D.
Format: Article
Language:English
Subjects:
Adult
Alemtuzumab
anti-thymocyte globulin
Antibodies, Monoclonal - therapeutic use
Antibodies, Monoclonal, Humanized - adverse effects
Antibodies, Monoclonal, Humanized - therapeutic use
Antilymphocyte Serum - therapeutic use
basiliximab
Cytomegalovirus
Female
Graft Rejection - etiology
Graft Rejection - immunology
Graft Survival
Humans
Immunosuppressive Agents - therapeutic use
Infection - etiology
Kaplan-Meier Estimate
Kidney Transplantation - adverse effects
Kidney Transplantation - immunology
Kidney Transplantation - methods
Leukopenia - etiology
Male
Middle Aged
Recombinant Fusion Proteins - therapeutic use
renal transplantation
Retrospective Studies
Risk Factors
Transplants & implants
Treatment Outcome
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary Between 1 January 2002 and 31 December 2007, our center performed 1687 adult renal transplants. A retrospective analysis was performed to compare outcomes between patients receiving alemtuzumab (n = 632) and those receiving either basiliximab (n = 690) or thymoglobulin (n = 125). Patients receiving alemtuzumab were younger (49 vs. 51 years, P = 0.02), had fewer HLA matches (1.7 vs. 2.0, P 
ISSN:0934-0874
1432-2277
DOI:10.1111/j.1432-2277.2012.01448.x